C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/13 (2006.01) A61K 39/395 (2006.01) A61P 37/00 (2006.01) C07K 16/28 (2006.01) C12N 15/10 (2006.01) C12N 15/79 (2006.01)
Patent
CA 2437963
A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-lle-lle-His (NYIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys- Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid seuqnce Ser-Gly- Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1', CDR2' and CDR3', CDR1' having the amino acid sequence Arg-Ala-Ser-Gln-Asn-lle-Gly-Thr-Ser-lle-Gln 8RASQNIGTSIQ), CDR', having the amino acid sequence Ser-Ser-Ser-Glu-Ser-lle-Ser (SSSESIS) and CDR3' having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chmieric or humanised antibody, useful as a pharmaceutical.
La présente invention concerne une molécule comportant un site de liaison à l'antigène, comprenant en séquence les régions hypervariables CDR1, CDR2 et CDR3, ladite CDR1 ayant la séquence d'acides aminés Asn-Tyr-Ile-Ile-His (NYlIH), ladite CDR2 ayant la séquence d'acides aminés Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) et ladite CDR3 ayant la séquence d'acides aminés Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT), par exemple, comprenant en outre en séquence les régions hypervariables CDR1', CDR2' et CDR3', CDR1' ayant la séquence d'acide aminés Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ), CDR2' ayant la séquence d'acides aminés Ser-Ser-Ser-Glu-Ser-IIe-Ser (SSSESIS), CDR3' ayant la séquence d'acides aminés Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), par exemple, un anticorps chimérique ou humanisé, utile en tant que médicament.
Aszodi Andras
Aversa Gregorio
Carballido Herrera Jose M.
Hall Bruce M.
Kolbinger Frank
Fetherstonhaugh & Co.
Novartis Ag
LandOfFree
Therapeutic binding molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic binding molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic binding molecules will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1477538